In the BioHarmony Drug Report Database
Natalizumab
Tysabri (natalizumab) is an antibody pharmaceutical. Natalizumab was first approved as Tysabri on 2004-11-23. It is used to treat crohn disease and multiple sclerosis in the USA. It has been approved in Europe to treat multiple sclerosis. The pharmaceutical is active against integrin alpha-4.
Trade Name
|
Tysabri |
|---|---|
Common Name
|
natalizumab |
ChEMBL ID
|
CHEMBL1201607 |
Indication
|
crohn disease, multiple sclerosis |
Drug Class
|
Monoclonal antibodies: humanized, immunomodulating |
Image (chem structure or protein)
